Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy

Autor: S.D. Kim, Evan Bradner, Colin G. Cameron, Marta E. Alberto, Patrick C. Barrett, Gagan Deep, John Roque, Ge Shi, Nino Russo, Sherri A. McFarland, David von Dohlen, Houston D. Cole, Liubov M. Lifshits
Rok vydání: 2020
Předmět:
Zdroj: Inorg Chem
ISSN: 1520-510X
Popis: Hypoxia presents a challenge to anticancer therapy, reducing the efficacy of many available treatments. Photodynamic therapy (PDT) is particularly susceptible to hypoxia given that its mechanism relies on oxygen. Herein, we introduce two new osmium-based polypyridyl photosensitizers that are active in hypoxia. The lead compounds emerged from a systematic study of two Os(II) polypyridyl families derived from 2,2′-bipyridine (bpy) or 4,4′-dimethyl-2,2′-bipyridine (dmb) as coligands combined with imidazo[4,5-f][1,10]phenanthroline ligands tethered to n=0–4 thiophenes (IP-nT). The compounds were characterized and investigated for their spectroscopic and (photo)biological activities. The two hypoxia-active Os(II) photosensitizers had n=4 thiophenes, with the bpy analog 1–4T being the most potent. In normoxia, 1–4T had low nanomolar activity (EC(50)=1–13 nM) with phototherapeutic indices (PI) ranging from 5,500 to 55,000 with red and visible light, respectively. Submicromolar potency was maintained even in hypoxia (1% O(2)), with light EC(50) and PI values of 732–812 nM and 68–76, respectively — among the largest PIs to date for hypoxic photoactivity. This high degree of activity coincided with a low-energy, long-lived (0.98–3.6 μs) mixed-character intraligand-charge-transfer ((3)ILCT)/ligand-to-ligand charge transfer ((3)LLCT) state only accessible in quaterthiophene complexes 1–4T and 2–4T. The coligand identity strongly influenced the photophysical and photobiological results in this study, whereby the bpy coligand led to longer lifetimes (3.6 μs) and more potent photocytotoxicity relative to dmb. The unactivated compounds were relatively nontoxic both in vitro and in vivo. The maximum tolerated dose (MTD) for 1–4T and 2–4T in mice was ≥ 200 mg kg(−1), an excellent starting point for future in vivo validation.
Databáze: OpenAIRE